Cover photo
International Myeloma Foundation
65 followers|16,446 views


This week's ‪#‎MyelomaMinute‬ is out with news on:‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬
-- Daratumumab Shows 36% Efficacy Rate in Treating Relapsed and Refractory Multiple Myeloma in Study
-- Dr. Durie’s latest post: 2 Top Medical Journals Weigh in on Potential Danger of Toxic Chemicals
-- Expanded Access Program for Elotuzumab
-- Watch the IMF Patient & Family Seminar Live Stream Replay on IMF TV
-- Join the IMF's 9th Annual Comedy Celebration and Support Myeloma Research
and many upcoming events!
Add a comment...
Register for the IMF’s “Veterans Against Myeloma Teleconference Series” free webinar on Thursday, September 17 at 7 PM ET, 4 PM PT. Speakers Sandy Kurtin, RN, MS, AOCN®, ANP and Susan Leigh, RN, retired Lieutenant, US Army, and Vietnam Veteran will discuss how veterans with multiple myeloma deal with the disease and how they can navigate the VA and other agencies to optimize their resources. Register here:
Add a comment...
More than 900 patients have been treated with selinexor in phase I and phase II clinical trials and in an ongoing phase I clinical trial, selinexor in combination with low-dose dexamethasone demonstrated favorable responses in myeloma patients. Read more about the selinexor STORM trials here:
Add a comment...
Debbie Birns, IMF's Medical Editor, talks about the importance of keeping an electronic copy of your medical records. Learn what you need to know and watch this informative 8-minute video on IMF TV, here:
Add a comment...
Improving Lives ∙ Finding the Cure
Founded in 1990, the International Myeloma Foundation (IMF) is dedicated to our mission: to improve the quality of life of myeloma patients while working toward prevention and a cure.

Your support helps us provide a wide range of programs and services to the myeloma community in the areas of Research, Education, Support, and Advocacy.

Research: The International Myeloma Foundation is the leader in globally collaborative myeloma research. The IMF brings together the world’s leading experts in the most successful and unique way through the International Myeloma Working Group (IMWG), which is charting the course to a cure, mentoring the next generation of innovative investigators, and improving lives through better care.

In 2012, the IMF launched the Black Swan Research Initiative, a unique project to develop a definitive cure for myeloma. The BSRI now joins the groundbreaking and innovative myeloma research the IMF has actively supported for more than twenty years.

Education: The IMF’s educational seminars and workshops provide up-to-date information to myeloma patients and their families directly from leading myeloma researchers and practicing clinicians. Our library of over 100 publications is updated annually and available free of charge to all who need them.

Support: The IMF maintains a network of over 150 support groups worldwide and provides training for the hundreds of men and women who volunteer to lead these group in their communities Our toll-free Hotline (800-452-CURE) answers questions and provides information and support to thousands of families each year.

Advocacy: The IMF Advocacy program helps guide individuals to advocate for critical health issues that affect the Myeloma community. The IMF leads the Patient Equal Access Coalition to PEAC and the State Patient Equal Access Coalition (SPEAC) to advocate for parity in insurance coverage for oral cancer therapies.

Learn more about the way the IMF is helping to improve the quality of life of myeloma patients while working toward prevention and a cure. Contact us at 800-452-CURE or visit
Contact Information
Contact info
800-452-CURE, 818-487-7455
12650 Riverside Drive, Suite 206 North Hollywood, CA 91607